Harvard geneticist David Sinclair’s seductive notion that aging is a treatable disease has helped companies he founded to raise more than $1 billion. The investors have almost nothing to show for it.
They made no claims to immortality. However, what they discussed at WGS 2026 in Dubai seemed to subtly contradict the way we ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Local researchers including ...
Morning Overview on MSN
Billionaires chase immortality as Harvard-backed startup wins FDA nod for 1st partial de-aging trial
The race to slow, halt, or even reverse aging has moved from science fiction into the regulatory record. A Harvard-linked startup, Life Biosciences, has secured clearance from the U.S. Food and Drug ...
Morning Overview on MSN
World’s 1st human aging reversal trial quietly gets underway
The first clinical attempt to make human beings biologically younger is no longer a thought experiment. A small gene therapy trial, cleared quietly by regulators in the United States, is now moving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results